HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Supplement Market Regulation: Depression Claim, Undisclosed Drug, COVID Tincture

Executive Summary

FDA warns 10 businesses they’re marketing unapproved and misbranded drugs by making claims for supplements to treat depression. Supplement also found with one of, if not the most common violations in the US supplement market: it contained an undisclosed ED drug.

You may also be interested in...



COVID-19 Stress Drives Anxiety-Reducing Supplement Sales Up 79% In US Since 2018

Sales for anxiety/stress relief dietary supplements in 2020 grew 79% from 2018, eclipsing growth of 22% for general herbal supplements during the same comparison period. Stress-relief supplements including St. John’s wart, ashwagandha and cannabinoids continue to grow in popularity.

More ED-Spiked Supplements Sold On Amazon Recalled Following US FDA Tests

US FDA published announcement by two firms recalling products they sold under the brand Thumbs Up 7 and that were found in FDA tests to contain undeclared sildenafil and tadalafil.

US FDA Concern Rekindled After Finding ED-Spiked Supplements Sold On Amazon

NJ firms S&B Shopper and Namoo Enterprise recall products after FDA tests found undisclosed erectile dysfunction drugs sildenafil and tadalafil. FDA officials Imperial Extreme 2000 and Namoo’s PremierZen Black 5000 capsules on Amazon.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel